Summary of the technology
PROJECT ATLAS™ is an IP and know-how platform that turns scientific peptide capabilities into transferable commercial assets. The portfolio covers 11 technology platforms spanning peptide stability/formulation, advanced delivery, professional dermocosmetic engines, transmucosal delivery, bioprocess media, and adjacent enabling layers. Seeking industrial partners, CDMOs, beauty/pharma companies and intermediaries for asset sale, licensing or strategic transaction — under NDA for detailed diligence.
Details of the Technology Offer
Technology Description:
ATLAS is designed as a platform, not a single product. The same technological base supports multiple product families, commercial configurations and go-to-market paths.
Architecture:
- IP + know-how foundations → technology layers (stability, delivery, matrix, sensing, process) → repeatable product families → revenue / licensing / strategic transaction options.
Two value speeds:
- Commercial engines (P07, P11) — identifiable markets, products, channels and evidence.
- Technology / licensing layers (P01, P05, P06 + options) — reusable enablers for partners without requiring ATLAS to manufacture everything in-house.
Portfolio scope (public, non-enabling overview):
- P07 ATLAS Peripheral GLP-1 Companion Engine™ — multi-target skin/hair platform addressing visible changes during accelerated body-composition shifts (dermocosmetic / aesthetics / haircare / consumer health).
- P11 PeptiLaser Recover™ — professional post-procedure recovery platform (peptide-based topical + protocol + replenishment B2B).
- P01 STAB-X™ — reusable stability & formulation architecture for high-value peptide products (pharma / biotech / CDMO / ingredients).
- P05 PDNV™ — plant-derived nanovesicle delivery/ingredient platform for topical, transdermal and mucosal routes.
- P06 ATLAS Transmucosal Delivery Engine™ — directional transmucosal delivery architecture (incl. buccal concepts) adaptable to peptide payloads.
- Additional strategic options: physiological access modulation (P02), cyber-physical trusted delivery (P03), programmable biofunctional matrix (P04), smart peptide packaging/biosensor (P08), dipeptide–metal coordination ingredients (P09), non-GMM bioprocess media (P10).
Owner: Iniciativas de Valor Añadido S.L. (Spain) — PROJECT ATLAS / Health Innovation Unit.
Public materials are commercial and non-enabling. Composition, process parameters and confidential know-how are shared only under suitable confidentiality and diligence.
Contact via Innoget RFI. Next step: short call → NDA → access to teaser dossier / data room under diligence.
Specifications:
- 11 IP platforms · 69 product families · 120+ potential configurations/SKUs (portfolio design; not a claim of launched SKUs).
- Asset types: IP rights packages + trade secrets/know-how + preliminary FTO workstream materials (details under NDA).
- Deal structures contemplated: full portfolio or package sale, selective licensing, white-label / territorial models, process/know-how transfer for manufacturing enablers.
- Development posture: platforms at varying maturity; commercial engines prioritized for near-term productization; licensing layers and strategic options available for partner-led validation.
- Regulatory note: intended pathways depend on product classification (cosmetic / professional / other). No medicinal claims are made in this public offer.
New and Innovative Aspects:
- Closes the translation gap from valuable peptide science to usable, repeatable, monetizable assets (formulation, delivery, evidence path, channel).
- Structured optionality: monetize asset-by-asset or as a set, without forcing each platform into a standalone operating company.
- Enables partners (CDMOs, beauty, pharma, ingredient houses) to adopt layers (stability, delivery, media) without rebuilding the same enabling stack.
- Commercial narrative deliberately non-enabling: enough for qualified RFIs; diligence and confidential packs under NDA.
Applications:
- Dermocosmetic and aesthetic markets (skin, hair, post-procedure professional care).
- Peptide therapeutics adjacent formulation/stability challenges (partner CDMO / biotech).
- Advanced delivery (topical, transmucosal, carrier systems).
- Bioprocess upstream media for peptide fermentation workflows (non-GMM media concept).
- Smart packaging / integrity sensing and related enabling layers for sensitive payloads.
- Ideal counterparties: CDMOs, beauty/dermocosmetic groups, pharma/biotech BD, ingredient companies, IP intermediaries and open-innovation desks seeking transferable intangible packages.
Attached documents
Related Keywords
